Amgen

Carbon per million dollars of revenue. The legacy industry-standard reference (CDP, MSCI). Useful for cross-sector context, but distorted by margin — high-margin firms appear artificially efficient. Read alongside the operational and asset intensities for the full picture.

OpEx (operating expenditure) is the running cost of the business — staff, services, energy, materials. This shows how carbon-intensive operations are per million dollars of spend. Removes the margin distortion that revenue-based ratios introduce.

EVIC (Enterprise Value Including Cash) is the firm's total capital footprint — equity + debt + cash + minority interest. The EU's standard intensity measure (SFDR PAI 3) — answers: how much carbon does each million of capital deployed in this business produce?

PP&E (Property, Plant & Equipment) plus leased real-estate assets is the firm's physical infrastructure on the balance sheet. This shows the carbon intensity of that physical footprint — uses Scope 1+2+3 for consistency with the other headline intensities. Surfaces stranded-asset risk for asset-heavy firms.

• · Puro.earth Registry
• · berkeley_voluntary_registry

Amgen sourced 90% renewable electricity across its facilities in 2024. The new Ohio biomanufacturing site is the first fully electric Amgen facility, with an on-site solar array sized to generate 2,038 MWh annually delivered back to the local grid. The corporate aim is for all Amgen facilities, wherever feasible, to procure 100% renewable energy by 2027. Purchased renewable energy rose from 480,000 GJ in 2019 to 1,210,000 GJ in 2024, while purchased fossil energy dropped from 975,000 to 132,000 GJ over the same period.

In 2024 Amgen began augmenting its innovative and energy-efficient project portfolio with high-quality Scope 1 carbon emission offsets to assist progress toward its 2027 carbon neutrality ambition. 40,000 MT of high-quality carbon offsets were included in the 2024 Scope 1 figure. Amgen describes them as 'offsets' rather than removals and does not distinguish durable removals (DAC, BECCS, biochar) from avoidance credits.

• Commercial fleet electrification — 1,800 EVs by 2027

  Amgen increased EV adoption to 687 vehicles across the US, EU, Japan, Australia and South Korea in 2024, moving toward 1,800 EVs (30% of the total fleet) by 2027. In the US, Japan and EU, field-based employees must select all-electric or hybrid vehicles. 2024 fleet carbon emissions were 33% lower than the 2019 baseline.

• Process water and energy efficiency at manufacturing sites

  At the Puerto Rico facility (Amgen's largest manufacturing site), process control optimisation reduced potable water consumption by 91,417 m³ in 2024. Across operations, 198,000 m³ of water-saving projects were executed and over 300 MT of waste-reduction projects implemented, even as total throughput grew with the operational footprint.

• Amgen Ecovation™ biomanufacturing — fully electric, modular facility design

  Amgen's proprietary Ecovation™ biomanufacturing approach uses flexible, modular designs that require less space, are built faster, cost less to operate, and have lower environmental impact than traditional plants. The new Ohio facility is fully electric and the North Carolina facility achieved Fitwel certification. These plants are central to delivering the 2027 Scope 1+2 carbon neutrality target.

• Scope 3 supplier engagement on science-based targets

  Amgen has an SBTi-validated Scope 3 supplier target to engage 73% of suppliers by spend in key categories to support their adoption of science-based targets by 2027. Science-based goal setting has been embedded into sourcing criteria. Progress described as on track at end of 2024.